Literature DB >> 25694527

Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to Pseudomonas aeruginosa.

Yukihiro Hamada1, Christina A Sutherland2, David P Nicolau3.   

Abstract

The CLSI reduced the cefepime Enterobacteriaceae susceptibility breakpoint and introduced the susceptible-dose-dependent (S-DD) category. In this study, MICs were determined for a Gram-negative collection to assess the impact of this change. For Enterobacteriaceae, this resulted in <2% reduction in susceptibility, with 1% being S-DD. If applied to Pseudomonas aeruginosa, the % susceptibility (%S) dropped from 77% to 43%, with 34% being S-DD. The new breakpoints did little to the Enterobacteriaceae %S, but for P. aeruginosa, a profound reduction was seen in %S. The recognition of a S-DD response to cefepime should alert clinicians to the possible need for higher doses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25694527      PMCID: PMC4400738          DOI: 10.1128/JCM.03652-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  3 in total

1.  Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test.

Authors:  Laurent Dortet; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

2.  Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.

Authors:  Ronald N Jones; Jeffrey T Kirby; Paul R Rhomberg
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-10       Impact factor: 2.803

3.  Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Catharine C Bulik; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

  3 in total
  6 in total

1.  Monitoring Antimicrobial Resistance in the Food Supply Chain and Its Implications for FDA Policy Initiatives.

Authors:  Kelson Zawack; Min Li; James G Booth; Will Love; Cristina Lanzas; Yrjö T Gröhn
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.

Authors:  Christian M Gill; Elif Aktaş; Wadha Alfouzan; Lori Bourassa; Adrian Brink; Carey-Ann D Burnham; Rafael Canton; Yehuda Carmeli; Marco Falcone; Carlos Kiffer; Anna Marchese; Octavio Martinez; Spyros Pournaras; Harald Seifert; Abrar K Thabit; Maria Virginia Villegas; Lars F Westblade; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

3.  Impact of Cefepime Susceptible-Dose-Dependent MIC for Enterobacteriaceae on Reporting and Prescribing.

Authors:  Christina G Rivera; Prasanna P Narayanan; Robin Patel; Lynn L Estes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

4.  Markov Networks of Collateral Resistance: National Antimicrobial Resistance Monitoring System Surveillance Results from Escherichia coli Isolates, 2004-2012.

Authors:  William J Love; Kelson A Zawack; James G Booth; Yrjo T Grӧhn; Cristina Lanzas
Journal:  PLoS Comput Biol       Date:  2016-11-16       Impact factor: 4.475

5.  Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase.

Authors:  Ki Ho Park; Yong Pil Chong; Sung Han Kim; Sang Oh Lee; Mi Suk Lee; Heungsup Sung; Mi Na Kim; Yang Soo Kim; Jun Hee Woo; Sang Ho Choi
Journal:  Infect Chemother       Date:  2017-02-28

6.  Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia.

Authors:  Kap Sum Foong; Abigail L Carlson; Satish Munigala; Carey-Ann D Burnham; David K Warren
Journal:  Open Forum Infect Dis       Date:  2019-07-28       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.